170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated
General procedure: The dibromide was added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (39.1 mg, 78.0 mumol), KI (12.9 mg, 78.0 mumol) and K2CO3 (10.8 mg, 78.0 mumol) in CH3CN (2.50 mL) under N2 and stirred for 24 h at room temperature. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediate (130 mg). A solution of the intermediate was added to bis(pyridin-2-ylmethyl)amine (12.0 mg, 60.0 mumol), KI (9.96 mg, 60.0 mumol) and K2CO3 (8.30 mg, 60.0 mumol) in CH3CN (3.00 mL) under N2 and stirred at 80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediate. The intermediate was then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compound 16.
170161-27-0, As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.
Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI